Solid Biosciences (SLDB) Total Non-Current Liabilities (2018 - 2026)

Solid Biosciences has reported Total Non-Current Liabilities for 7 years, with the latest figure at $18.5 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 10.57% year-over-year to $18.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.5 million (down 10.57% YoY) and the FY2025 annual result came in at $19.1 million, down 9.93% from the prior year.
• Total Non-Current Liabilities eased to $18.5 million in Q1 2026 per SLDB's latest filing, from $19.1 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $48.5 million in Q4 2022 and troughed at $18.5 million in Q1 2026.
• A 5-year average of $23.7 million and a median of $20.9 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities sank 50.63% in 2023, then dropped 9.93% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $48.5 million in 2022, then tumbled by 50.63% to $23.9 million in 2023, then declined by 11.62% to $21.2 million in 2024, then retreated by 9.93% to $19.1 million in 2025, then fell by 3.04% to $18.5 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $18.5 million, $19.1 million, and $19.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.